Kimia Biosciences Limited (KIMIABL.BO)
- Previous Close
38.52 - Open
38.52 - Bid 37.11 x --
- Ask 39.50 x --
- Day's Range
38.52 - 40.00 - 52 Week Range
35.10 - 53.98 - Volume
450 - Avg. Volume
8,095 - Market Cap (intraday)
1.888B - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kimia Biosciences Limited manufactures and sells active pharmaceutical ingredients (APIs) in India. The company offers and develops APIs in the categories, including gastrintenstinal agents, anti-coagulants, anti-hypertensive, lipid lowering agents, vitamins, anti-histamine, anti-convulsant, central stimulant, anti-diabetic, and anti-bacterial, as well as anti-psychotic, anti-fungal, urologicals, anti-inflammatory, prokinetic agent, cholelithiasis agent, anti-asthmatic, anti-depressant, anti-acne, decongestant, and anti-virals. It exports its products. The company was formerly known as Laurel Organics Ltd and changed its name to Kimia Biosciences Limited January 2019. Kimia Biosciences Limited was incorporated in 1993 and is based in New Delhi, India.
www.kimiabiosciences.com250
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: KIMIABL.BO
View MorePerformance Overview: KIMIABL.BO
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KIMIABL.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KIMIABL.BO
View MoreValuation Measures
Market Cap
1.89B
Enterprise Value
1.89B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
8.48%
Return on Assets (ttm)
--
Return on Equity (ttm)
225.87%
Revenue (ttm)
1.11B
Net Income Avi to Common (ttm)
94.16M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
6.28M
Total Debt/Equity (mrq)
504.73%
Levered Free Cash Flow (ttm)
--